Gyre Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $29,105 | $22,519 | $37,195 | $30,564 |
Gross Profit | 26,896 | 21,292 | 35,452 | 28,936 |
EBITDA | -14,368 | -8,565 | 629 | 8,278 |
EBIT | -14,434 | -9,237 | -66 | 7,629 |
Net Income | -10,605 | -8,616 | -1,723 | 3,610 |
Net Change In Cash | 29,105 | 22,519 | 37,195 | 30,564 |
Free Cash Flow | -18,014 | 3,002 | -5,769 | 3,993 |
Cash | 43,287 | 37,501 | 37,070 | 40,402 |
Basic Shares | 100,637 | 91,344 | 102,940 | 102,701 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $116,588 | $105,757 | $113,450 | $102,290 |
Gross Profit | 111,172 | 101,873 | 108,814 | 97,497 |
EBITDA | 16,956 | 17,817 | 20,327 | 10,541 |
EBIT | 14,436 | 16,229 | 19,213 | 9,412 |
Net Income | 5,027 | 12,085 | -92,933 | 2,302 |
Net Change In Cash | 116,588 | 105,757 | 113,450 | 102,290 |
Free Cash Flow | -180 | -6,769 | 17,306 | 5,679 |
Cash | 37,070 | 11,813 | 33,509 | 25,175 |
Basic Shares | 103,180 | 102,293 | 65,831 | 75,686 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.12 |
2026-03-31 | -$0.10 |
2025-12-31 | $0.04 |
2025-09-30 | $0.03 |